江汉大学学报（自然科学版）2025，Vol.53Issue(2)：79-86,8.DOI:10.16389/j.cnki.cn42-1737/n.2025.02.009
常规剂量的阿美替尼治疗肺腺癌引起肌酸激酶异常升高1例报告及文献复习
Abnormal Elevation of Creatine Kinase During Routine Doses of Aumolertinib Used Against Lung Adenocarcinoma:A Case Report and Literature Review
摘要
Abstract
Objective Exploring the characteristics of abnormal elevation of serum creatine kinase(CK)induced by the novel three representative epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)aumolertinib,its relationship with dosage,related serological changes,and its impact on treatment decision-making.Methods The clinical manifestations,imaging,and pathological features of a patient with lung adenocarcinoma treated with a routine dose of aumolertinib were analyzed,and the literature was reviewed.Results In a 59-year-old female patient with lung adenocarcinoma and EGFR21 exon L858R mutation,CK increased to a peak of 760 U/L(CTCAE grade 3 or above)on 167 days after aumolertinib 110 mg/d treatment,and CK decreased to the normal range on 30 days after withdrawal.During this period,there were no symptoms such as muscle pain,and no evidence of cardiac toxicity or myositis was found in serological and imaging examinations.After aumolertinib was reduced by 110 mg weekly,CK stabilized in the CTCAE level 1 range.Conclusion Asymptomatic elevation of CK may occur during treatment with aumolertinib.The long-term effects of sustained CK elevation on cardiovascular function in patients and the intervention strategies for CK elevation are still uncertain.It is recommended to closely observe clinical symptoms such as muscle pain and monitor serum CK levels during the treatment with aumolertinib.关键词
阿美替尼/肌酸激酶/肺腺癌/表皮生长因子受体-酪氨酸激酶抑制剂Key words
aumolertinib/creatine kinase/lung adenocarcinoma/EGFR-TKIs分类
临床医学引用本文复制引用
周玉琳,李瑞琪,孙文,陈辉,李敏,冯觉平..常规剂量的阿美替尼治疗肺腺癌引起肌酸激酶异常升高1例报告及文献复习[J].江汉大学学报（自然科学版）,2025,53(2):79-86,8.基金项目
国家重大公共卫生服务项目补助资金-国家癌症早诊早治项目(鄂卫办发[2023]5号) （鄂卫办发[2023]5号）
武汉市"323"攻坚-癌症防治行动专项经费项目(2022-2023) （2022-2023）
